GWS
GBT

Glassman Wealth Services’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Glassman Wealth Services’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-7
Closed – – 2118
2022
Q1 		$0 Hold
7
– – ﹤0.01% 2052
2021
Q4 		$0 Hold
7
– – ﹤0.01% 2021
2021
Q3 		$0 Sell
7
-109
-94% -$3.2K ﹤0.01% 1890
2021
Q2 		$4K Buy
116
+111
+2,220% +$4.33K ﹤0.01% 1017
2021
Q1 		$0 Hold
5
– – ﹤0.01% 1699
2020
Q4 		$0 Sell
5
-31
-86% -$1.53K ﹤0.01% 1572
2020
Q3 		$2K Buy
36
+11
+44% +$699 ﹤0.01% 1063
2020
Q2 		$2K Hold
25
– – ﹤0.01% 929
2020
Q1 		$1K Hold
25
– – ﹤0.01% 1049
2019
Q4 		$2K Buy
25
+1
+4% +$59 ﹤0.01% 818
2019
Q3 		$1K Hold
24
– – ﹤0.01% 977
2019
Q2 		$1K Buy
24
+4
+20% +$230 ﹤0.01% 985
2019
Q1 		$1K Buy
+20
New +$983 ﹤0.01% 952

Other funds holding GBT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Glassman Wealth Services's GBT Position: Q2 2022 in Review

Glassman Wealth Services sold out of Global Blood Therapeutics, Inc. (GBT) in Q2 2022, closing a stake of 7 shares.

Glassman Wealth Services first reported a position in GBT in Q1 2019 and held it in 13 quarters. The position peaked at $4K in Q2 2021. 195 funds tracked by Wall St. Rank hold GBT as of Q2 2022.

  • Glassman Wealth Services reported no remaining Global Blood Therapeutics, Inc. position as of Q2 2022 after selling out during the quarter.
  • Glassman Wealth Services sold 7 Global Blood Therapeutics, Inc. shares in Q2 2022.
  • Glassman Wealth Services first reported a position in Global Blood Therapeutics, Inc. in Q1 2019 and held it in 13 quarters.
  • Glassman Wealth Services's Global Blood Therapeutics, Inc. position peaked at $4K in Q2 2021.
  • 195 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q2 2022.

Based on Glassman Wealth Services's 13F filing for Q2 2022, filed 4 Aug 2022.